Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;45(2):63-64.
doi: 10.18773/austprescr.2022.016. Epub 2022 Mar 4.

Fostemsavir for HIV-1 infection

No authors listed
Review

Fostemsavir for HIV-1 infection

No authors listed. Aust Prescr. 2022 Apr.
No abstract available

PubMed Disclaimer

References

    1. Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, et al. BRIGHTE Trial Team . Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med 2020;382:1232-43. 10.1056/NEJMoa1902493 - DOI - PubMed
    1. Lataillade M, Lalezari JP, Kozal M, Aberg JA, Pialoux G, Cahn P, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV 2020;7:e740-51. 10.1016/S2352-3018(20)30240-X - DOI - PubMed
    1. Ackerman P, Thompson M, Molina JM, Aberg J, Cassetti I, Kozal M, et al. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. AIDS 2021;35:1061-72. 10.1097/QAD.0000000000002851 - DOI - PMC - PubMed
    1. Lagishetty C, Moore K, Ackerman P, Llamoso C, Magee M. Effects of temsavir, active moiety of antiretroviral agent fostemsavir, on QT interval: results from a phase I study and an exposure–response analysis. Clin Transl Sci 2020;13:769-76. 10.1111/cts.12763 - DOI - PMC - PubMed

LinkOut - more resources